Workflow
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Supernus PharmaceuticalsSupernus Pharmaceuticals(US:SUPN) GlobeNewswire News Roomยท2024-09-24 11:30

Core Insights - The article highlights the importance of raising awareness about ADHD, particularly in women, and emphasizes the role of Qelbree as a treatment option for managing ADHD symptoms [1][2][3] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases, including ADHD [11] - The company is committed to providing treatment options and education for individuals living with ADHD, as stated by its CEO, Jack A. Khattar [4] Product Information - Qelbree (viloxazine extended-release capsules) is a non-stimulant medication approved for the treatment of ADHD in patients aged 6 years and older, marking the first non-stimulant approved for adults in 20 years [3][5] - Qelbree is designed to be taken once daily and has no evidence of abuse or misuse, allowing for convenient refills without the need for a new prescription each month [3] Market Context - Approximately 10 million adults in the U.S. live with ADHD, and the article emphasizes the challenges they face in managing their symptoms, particularly during transitions like the start of the school year [2] - The article aims to empower individuals, especially women, to seek treatment options and advocate for their health [2][3]